Organon & Co. (NYSE:OGN) saw a downside of -1.11% to close Tuesday at $32.84 after subtracting -$0.37 on the day. The 5-day average trading volume is 1,542,520 shares of the company’s common stock. It has gained $33.54 in the past week. An average of 1,715,415 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,122,346.
OGN’s 1-month performance is -2.93% or -$1.04 on its low of $31.92 reached on 10/06/21. The company’s shares have touched a 52-week low of $27.25 and high of $38.75. YTD, OGN has lost -1.23%. However, the current price is down -15.25%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
Organon & Co. (OGN) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.19 for the sector. The company’s PE ratio for the last five years has touched a high of 4.360 and a low of 3.502. OGN stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.06.
Organon & Co.’s quick ratio for the period ended June 29 was 1.00, with the current ratio over the same period at 1.30 meaning that OGN stock is able to fulfill its debt obligations. The trailing 12-month EBITDA margin is 36.30%.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected OGN to announce $1.4 per share in earnings in its latest quarter, but it posted $1.72, representing a 22.90% surprise. EBITDA for the quarter stood at more than $480.0 million. OGN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 12.84 billion, with total debt at $9.64 billion. Shareholders hold equity totaling $253.54 million
Let’s look briefly at Organon & Co. (OGN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 46.11% to suggest the stock is trending Neutral, with historical volatility in this time period at 26.78%.
The stock’s 5-day moving average is $32.91, reflecting a +0.95% or $0.31 change from its current price. OGN is currently trading -1.74% above its 20-day SMA, -13.01% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +11.21%.
Stochastic %K and %D was 42.37% and 41.68% and the average true range (ATR) pointed at 0.83. The RSI (14) points at 47.34%, while the 14-day stochastic is at 40.89% with the period’s ATR at 0.88. The stock’s 9-day MACD Oscillator is pointing at -0.03 and -0.25 on the 14-day charts.
In the most recent analyst report for Organon & Co. (NYSE: OGN), Piper Sandler launched coverage with a Neutral rating. Analysts offering their rating for OGN stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate OGN as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is OGN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $35.00 and a high of $48.00, with their median price target at $40.00. Looking at these predictions, the average price target given by analysts is for Organon & Co. (OGN) stock is $40.29.